Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
NCT ID: NCT01496573
Last Updated: 2016-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
77 participants
OBSERVATIONAL
2011-12-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma
NCT01609803
Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
NCT01365962
Biomarkers in Patients With Advanced Rhabdomyosarcoma
NCT01668095
Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma
NCT01433237
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
NCT01493830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue microarray (TMA).
OUTLINE:
Archived tumor tissue samples are analyzed for CRKL expression.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Basic science (biomarker analysis)
Archived tumor tissue samples are analyzed for CRKL expression.
laboratory biomarker analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
laboratory biomarker analysis
Correlative studies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lee Helman, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Oncology Group
Monrovia, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-00094
Identifier Type: REGISTRY
Identifier Source: secondary_id
ARST12B4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.